NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has signed an agreement making Sayre Therapeutics the exclusive distributor of its Tissue of Origin (TOO) tumor-identification test in India and South Asia.
The test is a US Food and Drug Administration-approved microarray-based assay that analyzes the expression of 2,000 genes to identify the most likely tissue of origin for 15 common tumor types including breast, non-small cell lung, colorectal, kidney, thyroid, and prostate. It was developed by Pathwork Diagnostics and was later acquired by Response Genetics, which Cancer Genetics bought for $14 million late last year.
"We view this partnership with Sayre as an important milestone in making precision medicine increasingly available outside the US, especially in high-growth, high-demand markets like India," President and CEO Panna Sharma said in a statement.
Cancer Genetics said that Sayre has begun actively marketing the test in major metro areas in India and South Asia, and has held seminars and workshops with key opinion leaders and clinicians in those markets.
Additional terms of the deal were not disclosed.